New antibody aims to calm ulcerative colitis when other treatments fail
NCT ID NCT04882007
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether OSE-127, an antibody that blocks a key immune signal, can reduce disease activity in people with moderate to severe ulcerative colitis who have not responded to or cannot tolerate previous treatments. Participants are randomly assigned to receive either OSE-127 or a placebo, and neither they nor their doctors know which they receive. The main goal is to see if the drug improves a combined score of symptoms and endoscopic findings after 10 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OSE-127 (a monoclonal antibody that blocks the IL-7 receptor)
What this could lead to
If successful, OSE-127 could offer a new treatment option for people with ulcerative colitis who have not been helped by existing therapies.
What could go wrong
This is an early phase 2 study with a small number of participants, so results may not apply to everyone. The drug may not work better than placebo or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
301 Fairfield Medical Suite
Cape Town, South Africa
-
Acibadem City Clinic University Multiprofile Hospital for Active Treatment - EOOD, Clinic of Gastroenterology
Sofia, Bulgaria
-
Andrii Novak Transcarpathian Regional Clinical Hospital
Uzhhorod, Ukraine
-
Brest Regional Hospital
Brest, Belarus
-
CHU Liège
Liège, Belgium
-
Centrum Medyczne Med-Gastr
Lodz, Poland
-
Centrum Medyczne Medyk
Rzeszów, Poland
-
Centrum Opieki Zdrowotnej Orkan-med
Ksawerów, Poland
-
City Clinical Emergency Hospital
Minsk, Belarus
-
Clinexpert SMO
Budapest, Hungary
-
Digestive Diseases Centre GASTRO
Riga, Latvia
-
Dnipropetrovsk I.I. Mechnikov Regional Clinical Hospital - Dnipropetrovsk Regional Council
Dnipro, Ukraine
-
EVEX Hospitals JSC
Kutaisi, Georgia
-
Ekaterinburg City Clinical Hospital No. 14
Yekaterinburg, Russia
-
Gomel Regional Clinical Hospital
Homyel, Belarus
-
Grodno University Hospital
Grodno, Belarus
-
Groupe Santé CHC - Clinique du Mont Légia
Liège, Belgium
-
II. Sz Belgyogyasztai Intezet, Gasztroenterologia Debreceni Egyetem
Debrecen, Hungary
-
II. Sz. Belgyogyaszati Klinika, Semmelweis Egyetem
Budapest, Hungary
-
Institute of Clinical Cardiology
Tbilisi, Georgia
-
Israel-Georgia Medical Research Clinic Helsicore Ltd
Tbilisi, Georgia
-
JSC Clinic Jerarsi
Tbilisi, Georgia
-
Kryvyi Rih City Clinical Hospital #2
Kryvyi Rih, Ukraine
-
Kyiv Regional Clinical Hospital - Kyiv Regional Council
Kyiv, Ukraine
-
LLC Novosibirskiy Gastrocenter
Novosibirsk, Russia
-
Liepāja Regional Hospital
Liepāja, Latvia
-
Medical Center Asklepion
Sofia, Bulgaria
-
Medical Center Asklepion - Researches in humane medicine (EOOD)
Sofia, Bulgaria
-
Medical Center Healthy Family LLC
Novosibirsk, Russia
-
Medical Center Hera
Sofia, Bulgaria
-
Medical Center Hera EOOD
Sofia, Bulgaria
-
Medical Center Medconsult Pleven
Pleven, Bulgaria
-
Medical Center Medconsult Pleven - OOD
Pleven, Bulgaria
-
Medical Center OK!Clinic+ of International Institute of Clinical Studies LLC
Kyiv, Ukraine
-
Medical Center VIP Clinic
Varna, Bulgaria
-
Medical center VIP Clinic - OOD
Varna, Bulgaria
-
Medicome Sp. z o.o.
Oświęcim, Poland
-
Melita Medical
Wroclaw, Poland
-
Multiprofile Clinic Consilium Medulla Ltd
Tbilisi, Georgia
-
Municipal Institution City Clinical Hospital #6 - Therapeutic Department
Zaporizhzhya, Ukraine
-
Oddział Kliniczny Gastroenterologii Ogólnej i Onkologicznej
Lodz, Poland
-
Pauls Stradins Clinical University Hospital
Riga, Latvia
-
Polana-D
Daugavpils, Latvia
-
Prof. O.O. Salimov City Clinical Hospital #2 - Kharkiv City Council
Kharkiv, Ukraine
-
Prof. S.V. Ochapovskiy Regional Clinical Hospital No.1
Krasnodar, Russia
-
Ryzhikh State Coloproctology Research Center
Moscow, Russia
-
Saratov State Medical University
Saratov, Russia
-
State Budgetary Healthcare Institution of the Stavropol Region - Pyatigorsk Oncology Dispensary
Pyatigorsk, Russia
-
Ternopil University Hospital - Ternopil Regional Council
Ternopil, Ukraine
-
UMHAT Tsaritsa Yoanna - ISUL - EAD
Sofia, Bulgaria
-
UZ Leuven - Department of Gastroenterology and Hepatology
Leuven, Belgium
-
University Hospital Center Split
Split, Croatia
-
Vitebsk Regional Clinical Hospital
Vitebsk, Belarus
-
WIP Warsaw IBD Point Profesor Kierkus
Warsaw, Poland
-
West Regional Center of Modern Medical Technologies Ltd
Kutaisi, Georgia